These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 35022524)
1. Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective. Tran TN; Peeters M; Hoeck S; Van Hal G; Janssens S; De Schutter H Br J Cancer; 2022 Apr; 126(7):1091-1099. PubMed ID: 35022524 [TBL] [Abstract][Full Text] [Related]
2. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited. Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788 [TBL] [Abstract][Full Text] [Related]
3. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme. van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071 [TBL] [Abstract][Full Text] [Related]
4. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality. Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171 [TBL] [Abstract][Full Text] [Related]
5. Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex? Arana-Arri E; Idigoras I; Uranga B; Pérez R; Irurzun A; Gutiérrez-Ibarluzea I; Fraser CG; Portillo I; BMC Cancer; 2017 Aug; 17(1):577. PubMed ID: 28851318 [TBL] [Abstract][Full Text] [Related]
6. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test. Ribbing Wilén H; Blom J J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444 [TBL] [Abstract][Full Text] [Related]
7. The Impact of a Six-Year Existing Screening Programme Using the Faecal Immunochemical Test in Flanders (Belgium) on Colorectal Cancer Incidence, Mortality and Survival: A Population-Based Study. Tran TN; Hoeck S; De Schutter H; Janssens S; Peeters M; Van Hal G Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674409 [TBL] [Abstract][Full Text] [Related]
8. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test. Ribbing Wilén H; Saraste D; Blom J J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615 [TBL] [Abstract][Full Text] [Related]
9. Interval colorectal cancers after negative faecal immunochemical test in the New Zealand Bowel Screening Pilot. Saw KS; Sexton K; Frankish P; Hulme-Moir M; Bissett I; Parry S BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 38007223 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program. Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504 [TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening. Kooyker A; de Jonge L; Toes-Zoutendijk E; Spaander M; van Vuuren H; Kuipers E; van Kemenade F; Ramakers C; Dekker E; Nagtegaal I; van Leerdam M; Lansdorp-Vogelaar I Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3424-3432.e2. PubMed ID: 37619823 [TBL] [Abstract][Full Text] [Related]
12. One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain). Tourne-Garcia C; Perez-Riquelme F; Monteagudo-Piqueras O; Fraser CG; Yepes-Garcia P J Med Screen; 2022 Dec; 29(4):231-240. PubMed ID: 35578555 [TBL] [Abstract][Full Text] [Related]
13. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program. Chiu SY; Chuang SL; Chen SL; Yen AM; Fann JC; Chang DC; Lee YC; Wu MS; Chou CK; Hsu WF; Chiou ST; Chiu HM Gut; 2017 Feb; 66(2):293-300. PubMed ID: 26515543 [TBL] [Abstract][Full Text] [Related]
14. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing. van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499 [TBL] [Abstract][Full Text] [Related]
15. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening. Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896 [TBL] [Abstract][Full Text] [Related]
16. Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment. Ribe SG; Botteri E; Løberg M; Randel KR; Kalager M; Nilsen JA; Gulichsen EH; Holme Ø Int J Cancer; 2023 Apr; 152(7):1414-1424. PubMed ID: 36346118 [TBL] [Abstract][Full Text] [Related]
17. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test. Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260 [TBL] [Abstract][Full Text] [Related]
18. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round. Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211 [TBL] [Abstract][Full Text] [Related]
19. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening. Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England. Murphy J; Halloran S; Gray A BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]